Tempus AI Inc. announced that eight abstracts have been accepted for presentation at the 2026 ASCO Gastrointestinal Cancers Symposium, scheduled for January 8-10 in San Francisco, California. The presentations will highlight Tempus’ latest scientific and clinical research findings in gastrointestinal cancers, using their multimodal database to uncover insights in oncology. Notable studies include genomic profiling of epithelial neoplasms of the appendix and analysis of transcriptomic signatures predicting improved survival with platinum therapy in BRCA/PALB2 wild-type metastatic pancreatic cancer. The results of these studies will be presented at the upcoming symposium.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260108177484) on January 08, 2026, and is solely responsible for the information contained therein.